Daré Bioscience, Inc. (DARE)

NASDAQ: DARE · IEX Real-Time Price · USD
0.450
+0.020 (4.63%)
Feb 27, 2024, 12:13 PM EST - Market open
4.63%
Market Cap 42.39M
Revenue (ttm) 1,000,000
Net Income (ttm) -41.05M
Shares Out 98.56M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 364,754
Open 0.434
Previous Close 0.430
Day's Range 0.430 - 0.474
52-Week Range 0.270 - 1.150
Beta 1.03
Analysts Strong Buy
Price Target 6.00 (+1,233.33%)
Earnings Date Mar 28, 2024

About DARE

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Ms. Sabrina Martucci Johnson
Employees 25
Stock Exchange NASDAQ
Ticker Symbol DARE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for DARE stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target
$6.0
(1,233.33% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

There are no FDA-approved treatments for female sexual arousal disorder There are no FDA-approved treatments for female sexual arousal disorder

27 days ago - GlobeNewsWire

Daré Bioscience Announces Executive Team and Board of Directors Changes

SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement o...

4 weeks ago - GlobeNewsWire

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newborns Grant funds support activities that will aid the ...

5 weeks ago - GlobeNewsWire

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Trea...

7 weeks ago - GlobeNewsWire

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

$5 million at closing and up to $7 million of additional committed funding $5 million at closing and up to $7 million of additional committed funding

2 months ago - GlobeNewsWire

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary Dysmenorrhea Data Support Continued Clinical Development of DARE-PDM1 and its Po...

2 months ago - GlobeNewsWire

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options

2 months ago - GlobeNewsWire

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of $1.8 million triggered by achievement of first commercial milestone under license agreem...

3 months ago - GlobeNewsWire

Daré Bioscience to Participate in Three November Conferences

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that the company's President and CEO, Sabrina Martucci Johnson...

4 months ago - GlobeNewsWire

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Additional Analyses of Phase 2b Data Conducted in Population of Study Participants with Female Sexual Interest/Arousal Disorder (FSIAD), With Primary Complaint of Arousal Dysfunction

4 months ago - GlobeNewsWire

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it has entered into a definitive agreement with an instit...

6 months ago - GlobeNewsWire

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial Sale Ovaprene® (hormone-free monthly contraception) – Pivota...

7 months ago - GlobeNewsWire

Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced the publication of positive preliminary efficacy results from ...

7 months ago - GlobeNewsWire

Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p...

7 months ago - GlobeNewsWire

Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that the company's Chief Scientific Officer, David Friend, Ph....

8 months ago - GlobeNewsWire

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause

8 months ago - GlobeNewsWire

Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO...

9 months ago - GlobeNewsWire

Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, the Journal of the International Menopause Society

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the publication of results of its Phase 1/2 clinical study of D...

9 months ago - GlobeNewsWire

Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Clinical Study Topline Data XACIATO™ First Commercial ...

10 months ago - GlobeNewsWire

Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p....

10 months ago - GlobeNewsWire

Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET

11 months ago - GlobeNewsWire

Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 ...

1 year ago - GlobeNewsWire

Daré Bioscience to Present at the 35th Annual Roth Conference

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CE...

1 year ago - GlobeNewsWire

Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced the start of a Phase 1 study evaluating its development progra...

1 year ago - GlobeNewsWire

Daré Bioscience to Participate in Three February Conferences

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO...

1 year ago - GlobeNewsWire